Annexon, Inc. (ANNX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Company: Annexon, Inc.
Reporting Period: Quarter ended June 30, 2025 (Q2 2025)
Business Overview: Annexon is a clinical-stage biopharmaceutical company developing novel therapies for classical complement-mediated neuroinflammatory diseases. The company has no approved products and generates no revenue. Its primary focus is on three programs: tanruprubart (Guillain-Barré Syndrome), vonaprument (Geographic Atrophy), and ANX1502 (Autoimmune indications).
Capital Structure: As of August 11, 2025, there were 109,886,623 shares of common stock outstanding, excluding 38,543,577 shares issuable upon exercise of pre-funded warrants.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(49,156) | $(29,610) | $(103,512) | $(54,786) |
| Net Loss Attributable to Common Stockholders | $(51,013) | $(29,610) | $(105,369) | $(54,786) |
| Loss Per Share (Basic & Diluted) | $(0.34) | $(0.23) | $(0.71) | $(0.43) |
| Operating Expenses | $51,726 | $33,580 | $109,131 | $62,152 |
| Research & Development (R&D) | $44,160 | $25,026 | $92,339 | $45,989 |
| General & Administrative (G&A) | $7,566 | $8,554 | $16,792 | $16,163 |
| Cash, Cash Equivalents & Short-Term Investments | $227,017 | $312,017 | $227,017 | $312,017 |
| Accumulated Deficit | $(814,211) | $(627,285) | $(814,211) | $(627,285) |
Note: Cash and short-term investments decreased from $312.0 million at Dec 31, 2024 to $227.0 million at June 30, 2025.
Material Changes vs. Prior Period
- Increased R&D Spend: R&D expenses increased by 76% ($19.1 million) in Q2 2025 compared to Q2 2024. This was driven by:
- $8.6 million increase in clinical/nonclinical outside services (Phase 3 ARCHER II trial and FORWARD study initiation).
- $3.9 million increase in contract manufacturing (BLA preparation for tanruprubart and technology transfer for vonaprument).
- $3.5 million increase in personnel costs due to higher headcount.
- Decreased G&A: G&A expenses decreased by 12% ($0.99 million) in Q2 2025, primarily due to reduced consulting/professional services and amortization of high fair-value stock options, partially offset by higher headcount.
- Deemed Dividend: A $1.9 million deemed dividend was recognized in Q2 2025 due to the modification of common warrants (extending term to June 2026 and removing cashless exercise option). This was recorded in additional paid-in capital with no net impact on stockholders' equity due to the accumulated deficit.
- Investment Activity: Net cash provided by investing activities was $170.7 million for the six months ended June 30, 2025, primarily due to $291.3 million in proceeds from maturities of available-for-sale securities, partially offset by $120.5 million in purchases.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management projects that existing cash and short-term investments ($227.0 million) will fund operations and capital expenditures into the fourth quarter of 2026. The company expects to continue incurring losses for the foreseeable future.
- Development Milestones:
- Tanruprubart (GBS): Marketing Authorization Application (MAA) submission in Europe expected in Q1 2026. Ongoing dialogue with FDA regarding BLA submission.
- Vonaprument (GA): Enrollment for Phase 3 ARCHER II trial completed in July 2025. Topline data expected in H2 2026.
- ANX1502: Proof-of-concept study in Cold Agglutinin Disease (CAD) ongoing; update expected by end of 2025.
- Key Risks:
- Capital Requirements: Substantial additional financing will be required to achieve goals; failure to obtain capital could force delays or termination of programs.
- Regulatory Uncertainty: No products approved; success depends on regulatory approval of product candidates. FDA may not accept data from foreign trials (e.g., GBS trials in Southeast Asia) without additional data.
- Manufacturing: Reliance on third-party suppliers for clinical and commercial manufacturing.
- Competition: Two FDA-approved therapies exist for Geographic Atrophy, which may impact patient recruitment and commercial potential.
Investor Verification Checklist
- Cash Runway: Verify the $227 million cash balance against the projected burn rate to confirm the "into Q4 2026" liquidity timeline.
- Warrant Dilution: Assess the impact of 38.5 million pre-funded warrants (exercisable at $0.001) and 8.1 million common warrants on potential dilution.
- GBS Regulatory Path: Monitor FDA feedback on the "generalizability package" required to accept data from Southeast Asian trials for U.S. approval.
- ARCHER II Trial Status: Confirm patient enrollment completion and timeline for H2 2026 topline data release.
- Deemed Dividend Impact: Review the $1.9 million deemed dividend related to warrant modifications and its accounting treatment.